Quest Diagnostics Receivables 2010-2024 | DGX

Quest Diagnostics receivables for the quarter ending September 30, 2024 were $1.376B, a 7.42% increase year-over-year.

  • Quest Diagnostics receivables for 2023 were $1.21B, a 1.26% increase from 2022.
  • Quest Diagnostics receivables for 2022 were $1.195B, a 16.9% decline from 2021.
  • Quest Diagnostics receivables for 2021 were $1.438B, a 5.39% decline from 2020.

Quest Diagnostics Receivables 2010-2024 | DGX

  • Quest Diagnostics receivables for 2023 were $1.21B, a 1.26% increase from 2022.
  • Quest Diagnostics receivables for 2022 were $1.195B, a 16.9% decline from 2021.
  • Quest Diagnostics receivables for 2021 were $1.438B, a 5.39% decline from 2020.
Related Stocks
Company NameMarket
Cap
Fresenius SE (FSNUY)$19.5B
DaVita (DVA)$12.9B
Encompass Health (EHC)$10B
Chemed (CHE)$8.2B
Elanco Animal Health (ELAN)$6.6B
RadNet (RDNT)$5.9B
Option Care Health (OPCH)$3.7B
Amedisys (AMED)$2.9B
LifeStance Health (LFST)$2.8B
Astrana Health (ASTH)$2.3B
Addus HomeCare (ADUS)$2.2B
U.S Physical Therapy (USPH)$1.4B
Aveanna Healthcare Holdings (AVAH)$1.1B
Pennant (PNTG)$1.1B
Atai Life Sciences (ATAI)$290M
Daxor (DXR)$43M
MEDIROM Healthcare Technologies (MRM)$15M
Psychemedics (PMD)$14M
ATI Physical Therapy (ATIP)$8M
Ontrak (OTRK)$8M
IMAC Holdings (BACK)$1M